Compare BLD & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | AXSM |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.0B |
| IPO Year | 2015 | 2015 |
| Metric | BLD | AXSM |
|---|---|---|
| Price | $412.82 | $237.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $444.33 | $211.12 |
| AVG Volume (30 Days) | ★ 812.1K | 661.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 3.73 | N/A |
| Revenue | ★ $2,384,249,000.00 | N/A |
| Revenue This Year | $13.36 | $57.24 |
| Revenue Next Year | $4.27 | $55.88 |
| P/E Ratio | $109.38 | ★ N/A |
| Revenue Growth | ★ 25.07 | N/A |
| 52 Week Low | $316.43 | $96.09 |
| 52 Week High | $559.47 | $260.19 |
| Indicator | BLD | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 50.49 |
| Support Level | $392.00 | $217.15 |
| Resistance Level | $425.32 | N/A |
| Average True Range (ATR) | 10.86 | 8.59 |
| MACD | 0.99 | -1.92 |
| Stochastic Oscillator | 65.11 | 28.50 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments are: Installation Services and Specialty Distribution. The Installation Services segment, which generates maximum revenue, installs insulation, commercial roofing, and other building products like glass and windows, rain gutters, doors, etc, mainly in the residential new construction market. The Specialty Distribution segment distributes building and mechanical insulation, insulation accessories, and other building product materials for the residential, commercial, and industrial markets. In addition to insulation and accessories, it distributes rain gutters, closet shelving, roofing materials, and other items. Geographically, the firm mainly operates in the U.S. and, to a lesser extent, in Canada.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.